Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

Stopped This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.

Conditions

• Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
• Ovarian Cancer

Interventions

• BIOLOGICAL: mRNA-2416
• BIOLOGICAL: Durvalumab

Sponsor

ModernaTX, Inc.